EUVIMEDEUVIMED entdecken
Open Access

Effectiveness of Oseltamivir in Hospitalized Children With Laboratory-Confirmed Influenza, 2014-2023

Kacie Rytlewski, Angela Dunn, Alissa O'Halloran, Jennifer Habeck, Isaac Armistead, Nisha B Alden, Darpun Sachdev, Pam Daily Kirley, James Meek, Kimberly Yousey-Hindes, Satoshi Kamidani, Kyle P Openo und 23 weitere

JAMA Pediatrics · 2026

DOI: 10.1001/jamapediatrics.2026.3376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Pediatrics, 2026. Verfasst von Kacie Rytlewski und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora. Hauptthemen laut MEDLINE: Oseltamivir, Influenza, Human, Antiviral Agents, Hospitalization. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance National organizations recommend antiviral treatment for hospitalized children with influenza; however, use in this setting has recently declined. Studies of oseltamivir effectiveness in children are limited by misclassification bias, unknown symptom onset date, and incomplete capture of antiviral use prior to admission.

Objective

To assess the association between oseltamivir receipt and intensive care unit (ICU) admission and hospital length of stay (LOS) among pediatric influenza-associated hospitalizations. Design, Setting, and Participants This cohort study used data that were obtained from the Influenza Hospitalization Surveillance Network (FluSurv-NET), which conducts US population-based surveillance for laboratory-confirmed influenza hospitalizations for all ages across 13 states. The study data include seasons 2014 to 2015 through 2022 to 2023, excluding 2020 to 2021. Participants included children aged younger than 18 years who were hospitalized with laboratory-confirmed influenza and for whom a respiratory symptom onset date was available. These data were analyzed from October 2024 through May 2026. Exposures Oseltamivir receipt as a time-dependent exposure. Main Outcome(s) and Measure(s) The primary outcome was time from symptom onset to ICU admission. Secondary outcome was time from admission to discharge (LOS). Adjusted Cox proportional hazard models (aHR) with oseltamivir receipt as a time-dependent exposure were used.

Results

After exclusions, 6044 influenza cases were included in the primary ICU analysis, of whom 4240 (70.2%) received oseltamivir, and 7103 cases were included in the secondary LOS analysis, of whom 5746 (80.9%) received oseltamivir. In the ICU analysis, the median (IQR) age was 3 (1-7) years, 3382 (56%) were male and 3721 (44%) were female, and 2937 (49%) had 1 or more medical comorbidity—the most common of which was asthma in 1547 children (26%). In adjusted models, compared with untreated children, oseltamivir treatment reduced the hazard of ICU admission (aHR, 0.69; 95% CI, 0.60-0.80) and shortened LOS (analyzed as hazard of hospital discharge; aHR, 1.13; 95% CI, 1.06-1.21). Conclusions and Relevance In this cohort of children hospitalized with influenza, oseltamivir treatment was significantly associated with a reduced risk of ICU admission by 31% and decreased hospital LOS. These findings demonstrate the benefits of oseltamivir receipt and support current national recommendations for oseltamivir treatment as soon as possible in children hospitalized with suspected or laboratory-confirmed influenza.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OseltamivirInfluenza, HumanAntiviral AgentsHospitalizationHumansChild, PreschoolFemaleChildMaleInfantLength of StayUnited StatesAdolescentTreatment OutcomeCohort StudiesChild, Hospitalized

Substanzen

OseltamivirAntiviral Agents

Autor:innen und Institutionen

  • Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora.
  • Adult and Child Center for Outcomes Research and Delivery Science, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora.
  • Influenza Division, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Goldbelt Professional Services, Chesapeake, Virginia.
  • Colorado Department of Public Health and Environment, Denver.
  • California Department of Public Health, Richmond.

Zitieren

APA

Rytlewski, K., Dunn, A., O'Halloran, A., Habeck, J., Armistead, I., Alden, N. B., Sachdev, D., Daily Kirley, P., Meek, J., Yousey-Hindes, K., Kamidani, S., Openo, K. P., Ryan, P. A., Monroe, M., Kim, S., Urlaub, E., Lynfield, R., McMahon, M., Smelser, C. B., …, & Rao, S. (2026). Effectiveness of Oseltamivir in Hospitalized Children With Laboratory-Confirmed Influenza, 2014-2023. JAMA Pediatrics. https://doi.org/10.1001/jamapediatrics.2026.3376

Vancouver

Rytlewski K, Dunn A, O'Halloran A, Habeck J, Armistead I, Alden NB, et al. Effectiveness of Oseltamivir in Hospitalized Children With Laboratory-Confirmed Influenza, 2014-2023. JAMA Pediatrics. 2026. doi:10.1001/jamapediatrics.2026.3376

BibTeX
@article{Rytlewski2026,
  author = {Rytlewski, Kacie and Dunn, Angela and O'Halloran, Alissa and Habeck, Jennifer and Armistead, Isaac and Alden, Nisha B and Sachdev, Darpun and Daily Kirley, Pam and Meek, James and Yousey-Hindes, Kimberly and Kamidani, Satoshi and Openo, Kyle P and Ryan, Patricia A and Monroe, Maya and Kim, Sue and Urlaub, Elizabeth and Lynfield, Ruth and McMahon, Melissa and Smelser, Chad B and Shaw, Yomei and Barney, Grant and Rowlands, Jemma V and Tesini, Brenda and Felsen, Christina and Lung, Krista and Sutton, Melissa and Thomas, Ann and Talbot, H Keipp and Schaffner, William and George, Andrea and Staten, Holly and Cataldi, Jessica R and Dominguez, Samuel R and Bozio, Catherine H and Rao, Suchitra},
  title = {Effectiveness of Oseltamivir in Hospitalized Children With Laboratory-Confirmed Influenza, 2014-2023},
  journal = {JAMA Pediatrics},
  year = {2026},
  doi = {10.1001/jamapediatrics.2026.3376}
}
Kostenlos starten →